Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world remibrutinib in chronic urticaria (China, 24-week observational)
ChiCTR2600127540Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remibrutinib in chronic urticaria (CU) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: 7-day Urticaria Activity Score (UAS7) at Week 12. Started Jul 2026; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on ChiCTR2600127540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127540.